HOME >> MEDICINE >> NEWS
New agreement questions NHS relation with industry

The Department of Health's new clinical trials agreement raises questions about the NHS's relation with the drug industry, says an editorial published on bmj.com today.

Following the tragedy of the TGN1412 trial, the Department of Health announced last month that a model clinical trials agreement has been finalised. This provides a template that can be used by all NHS trusts for any clinical trial, without modification.

But before embracing this agreement with open arms, we should examine what it actually says and what the deeper implications might be, warns Professor Michael Goodyear of Dalhousie University, Canada.

The agreement is the product of a unique consortium of industry, government, and academia, but other organisations, such as the Central Office for Research Ethics Committees, are not mentioned, despite being central to many issues covered in the agreement.

The agreement also applies only to contract research (commercial, industry sponsored trials usually directed towards pharmaceutical product licensing). It does not apply to phase I testing with healthy volunteers (as in TGN1412), to studies initiated by investigators, to trials in which the sponsor merely provides funding, or to research in non-NHS institutions.

While collaboration is admirable, we must realise that the development of a business model for research is a primary motivation behind this initiative, says Goodyear. As the guidance document states, the NHS is being "harnessed" in what is essentially a competitive model.

A surprising and disturbing element of the agreement relates to the crucial principles of transparency and accountability in research. Rather than incorporating and upholding the new and widely supported standards for an open research culture, the agreement has embedded an older and more problematic industry standard.

And, given that this agreement appears at a time when public trust in the drug industry
'"/>

Contact: Emma Dickinson
edickinson@bmj.com
44-020-738-36529
BMJ-British Medical Journal
16-Nov-2006


Page: 1 2

Related medicine news :

1. Heading to Siberia: UH signs agreement with Russian Academy of Sciences
2. Research agreement to advance new imaging technology
3. Access to science enhanced by new NIH-ASH agreement
4. Patent laws and US trade agreements are hindering access to HIV treatment
5. Stevens in agreement with Competitive Technologies to commercialize Stevens IP worldwide
6. GE Healthcare and St. Josephs Hospital and Medical Center, Phoenix announce research agreement
7. New licensing agreement to maximize AIDS drug development
8. AstraZeneca and M. D. Anderson Cancer Center form umbrella scientific collaboration agreements
9. Microbicide field praises agreement to license new AIDS drugs
10. Implementing European Space Policy: Key ESA/EC agreement on Earth Observation data signed today
11. Proteome Systems signs agreement with Prince Henrys Institute for Ovarian Cancer Diagnostic Test

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: New agreement questions NHS relation with industry

(Date:2/28/2015)... The MCA Youth Empowerment Conference aims to ... and gears towards the goal for a better future ... talks in smaller groups will be held after the ... Leadership, Entrepreneurship, Healthcare, Social and Volunteerism, Women and Youth ... , Young adults aged between 18-30 years ...
(Date:2/28/2015)... In a recent episode of SCI TV ... Athlete Development Services and Consultancy talks with Joshua ... development and player engagement during and after their careers. ... face and how off-field activities are a critical component ... in athlete development issues while in graduate school coaching ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 The Heart ... now a distributor of the machine. The Heart Fit ... their license, like a franchise model. The goal is ... and reverse heart disease. To buy External Counterpulsation ... Clinic can help individuals through this process and achieve ...
(Date:2/28/2015)... Mew and Company, a Vancouver corporate tax ... business consulting services in addition to a variety of ... succession planning. Company finances are a complicated matter that ... of this, complex Canadian tax laws can make it ... result, Mew and Company works to advise their clients ...
(Date:2/28/2015)... CA (PRWEB) February 28, 2015 A ... a promising new gene therapy procedure for the treatment ... blindness in patients. Authored by Dr. Robert ... and published in the Lancet Medical Journal on January ... from choroideremia, a rare genetic disorder that mostly affects ...
Breaking Medicine News(10 mins):Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2
(Date:2/27/2015)... Roughly three-quarters of pharmacists said they ... interchangeable biosimilar for its branded biologic counterpart if ... according to a survey published in the Academy ... Managed Care & Specialty Pharmacy (JMCP). ... would feel as confident if the products had ...
(Date:2/27/2015)... WuXi PharmaTech (Cayman) Inc. (NYSE:  WX), a leading open-access ... biotechnology, and medical device industries with operations in ... States , congratulates our partner TaiMed Biologics for ... ibalizumab (TMB355). The FDA designates a drug as a ... combination with one or more other drugs, to treat ...
(Date:2/27/2015)... Feb. 27, 2015  Acsis Inc., the market leader ... announced today that John DiPalo , Acsis, Chief ... & Demand Chain Executive 2015 Provider Pro to ... leading initiatives to help prepare their companies, and customers, ... climate. This year,s list of Provider Pros to Know ...
Breaking Medicine Technology:Survey Published in AMCP's JMCP Finds Pharmacists Are Most Confident Substituting Interchangeable Biosimilars for Brand Biologics When Products Share Nonproprietary Name 2WuXi Congratulates TaiMed Biologics on Receiving Breakthrough Therapy Designation from U.S. FDA 2Acsis CSO John DiPalo Named Supply & Demand Chain Executive 2015 Pro to Know 2
Cached News: